GHRP-2 vs Hexarelin
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: Pure GH secretagogue research where CD36 cardiovascular confounding is undesirable vs. Cardiovascular research exploring CD36-mediated cardioprotection alongside GH release.
Quick Answers
Which is better, GHRP-2 or Hexarelin?
Neither compound has a universal evidence advantage. Research distinction: Pure GH secretagogue research where CD36 cardiovascular confounding is undesirable vs. Cardiovascular research exploring CD36-mediated cardioprotection alongside GH release.
What is the key difference between GHRP-2 and Hexarelin?
Hexarelin binds CD36 scavenger receptors in cardiac tissue, producing cardiovascular effects independent of GH release; GHRP-2 acts primarily through GHS-R1a for GH secretion without significant CD36 activity.
Evidence Comparison
GHRP-2: well-characterized GH secretagogue with dose-response data in humans. Hexarelin: similar GH potency but additionally studied for cardiovascular effects via CD36 receptor binding (Bodart 2002). Neither is approved. Hexarelin has a broader research profile; GHRP-2 has cleaner GH-specific data.
Evidence Context Favoring GHRP-2
Pure GH secretagogue research where CD36 cardiovascular confounding is undesirable.
Evidence Context Favoring Hexarelin
Cardiovascular research exploring CD36-mediated cardioprotection alongside GH release.
Side-by-Side Snapshot
| Evidence grade | GHRP-2: Level C Hexarelin: Level C |
|---|---|
| Research status | GHRP-2: Preclinical Hexarelin: Phase 2 |
| Primary category | GHRP-2: Growth Hormone Hexarelin: Growth Hormone |
| Cited studies | GHRP-2: 2 Hexarelin: 2 |